MedTrace Logo

A Food Effect Study of JAB-21822 in Healthy Subjects

NCT05875493 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2025-04-04

No results posted yet for this study

Summary

The primary objective of this study is to determine the effect of food in healthy participants on the bioavailability of JAB-21822 following single dose administration with and without a meal

Conditions

  • Food Effect in Healthy Participants

Interventions

DRUG

JAB-21822

2 discrete single doses

DRUG

JAB-21822

2 discrete single doses

Sponsors & Collaborators

  • Allist Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • He Qing B.Pharm · Beijing Gaobo Boren Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-12
Primary Completion
2023-06-14
Completion
2023-06-14

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05875493 on ClinicalTrials.gov